Dynamic T-Cell Reprogramming Modulates the Treatment Outcome of Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung Cancer.

Notably, a similar trend of enhanced pathway activation in nonresponsive tumors was already present prior to treatment, although the difference did not reach statistical significance (Figure 5D,E ).

also in 111,027 other papers